norfloxacin has been researched along with Neoplasms in 12 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group." | 6.66 | Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988) |
| "Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group." | 2.66 | Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988) |
| "The global pandemic of drug-sensitive cancers and the increasing threat from drug-resistant cancers make an urgent need to develop more effective anti-cancer candidates." | 2.61 | Quinolone hybrids and their anti-cancer activities: An overview. ( Gao, F; Wang, T; Xiao, J; Zhang, X, 2019) |
| "Trovafloxacin was also the most active agent tested against Gram-positive organisms, including ciprofloxacin-susceptible strains and most ciprofloxacin- and methicillin-resistant staphylococci and enterococci." | 1.30 | In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. ( Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azéma, J | 1 |
| Guidetti, B | 1 |
| Dewelle, J | 1 |
| Le Calve, B | 1 |
| Mijatovic, T | 1 |
| Korolyov, A | 1 |
| Vaysse, J | 1 |
| Malet-Martino, M | 1 |
| Martino, R | 1 |
| Kiss, R | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Chu, XM | 1 |
| Wang, C | 1 |
| Liu, W | 1 |
| Liang, LL | 1 |
| Gong, KK | 1 |
| Zhao, CY | 1 |
| Sun, KL | 1 |
| Gao, F | 1 |
| Zhang, X | 1 |
| Wang, T | 1 |
| Xiao, J | 1 |
| Abdelwahab, M | 1 |
| Salahuddin, N | 1 |
| Gaber, M | 1 |
| Mousa, M | 1 |
| Carratalá, J | 2 |
| Fernández-Sevilla, A | 2 |
| Tubau, F | 2 |
| Callis, M | 1 |
| Gudiol, F | 2 |
| Broun, ER | 1 |
| Wheat, JL | 1 |
| Kneebone, PH | 1 |
| Sundblad, K | 1 |
| Hromas, RA | 1 |
| Tricot, G | 1 |
| Del Favero, A | 1 |
| Menichetti, F | 1 |
| Dominguez, MA | 1 |
| Rolston, KV | 1 |
| Ho, DH | 1 |
| LeBlanc, B | 1 |
| Streeter, H | 1 |
| Dvorak, T | 1 |
| D'Antonio, D | 1 |
| Iacone, A | 1 |
| Fioritoni, G | 1 |
| Betti, S | 1 |
| Dell'Isola, M | 1 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Pantalone, V | 1 |
| Recchia, A | 1 |
| Piergallini, A | 1 |
| Casali, A | 1 |
| Verri, C | 1 |
| Paoletti, G | 1 |
| Tropea, F | 1 |
| Modugno, G | 1 |
| Frasca, AM | 1 |
| Ameglio, F | 1 |
| Tonachella, R | 1 |
| Gallo Curcio, C | 1 |
3 reviews available for norfloxacin and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Quinoline and quinolone dimers and their biological activities: An overview.
Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Bacteria; Dimerization; Humans; Neoplas | 2019 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
3 trials available for norfloxacin and Neoplasms
| Article | Year |
|---|---|
Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.
Topics: Acyclovir; Adult; Bacteremia; Bone Marrow Transplantation; Female; Fever; Fluconazole; Gram-Positive | 1994 |
Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteremia; Bacterial Infections; Female; Fever; Hum | 1992 |
Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Humans; Neoplasms; | 1988 |
6 other studies available for norfloxacin and Neoplasms
| Article | Year |
|---|---|
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum | 2009 |
Poly(3-hydroxybutyrate)/polyethylene glycol-NiO nanocomposite for NOR delivery: Antibacterial activity and cytotoxic effect against cancer cell lines.
Topics: Anti-Bacterial Agents; Bacteria; Cell Line, Tumor; Cytotoxins; Drug Delivery Systems; Humans; Nanoco | 2018 |
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Drug Resistance, Microbial; Escherichia coli Infections; | 1995 |
The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Gram-Negativ | 1993 |
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; DNA, Bacterial; Drug Resistance, Micr | 1996 |
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter | 1997 |